Amyris Inc. announced that it expanded its existing production contract with Antibióticos de León. Amyris is disrupting markets by using the most advanced science and technology, including machine-learning and robotics to program yeast to create targeted molecules, at a lower cost and with sustainable supplies, resulting in sustainable methods of materials production. Amyris is the only company in the sector that has production capability at industrial scale, is evidenced by its clean manufacturing and commercialization of 15 products and its established supply agreements with market leaders across a range of business segments. Amyris is now expanding its production contract with ADL in order to provide additional, cost-effective manufacturing capability to meet the higher than expected demands from its partners.

ADL Biopharma is one of the first CMOs that Amyris has used to successfully produce farnesene.